Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 264

Sort by

Sort Order Select

Journal Articles

Blunted CD40-responsive enhancer activation in CREBBP -mutant lymphomas can be restored by enforced CD4 T-cell engagement

Blood (2025) 146 (2): 191–205.

https://doi.org/10.1182/blood.2024026664

Published: 2025

Includes: Supplemental data

Journal Articles

End points and Outcomes in Follicular Lymphoma: What should we measure, how, and why?

Mengyang Di, Matthew J. Maurer, Christopher R. Flowers

Blood blood.2024026978.

https://doi.org/10.1182/blood.2024026978

Published: 2025

Journal Articles

Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy

Blood (2025) 145 (8): 823–839.

https://doi.org/10.1182/blood.2024025366

Published: 2025

Includes: Supplemental data

Journal Articles

Real-world impact of differences in the WHO and ICC classifications of non-Hodgkin lymphoma: a LEO cohort study analysis

Blood (2024) 144 (19): 2063–2066.

https://doi.org/10.1182/blood.2024025681

Published: 2024

Includes: Supplemental data

Journal Articles

Developing Novel Cellular Therapies for Cutaneous T Cell Lymphoma (CTCL): Combining Immunopeptidomics and Endogenous T Cell (ETC) Therapy Platforms to Identify and Target Shared CTCL-Associated Antigens

Casey Bermack, Ke Pan, Yulun Chiu, Luis Malpica, Swaminathan P Iyer, Christopher R. Flowers, Cassian Yee

Blood (2024) 144 (Supplement 1): 3435.

https://doi.org/10.1182/blood-2024-207926

Published: 2024

Journal Articles

Utilizing Synthetic Individual Patient Level Cohorts from Machine Learning on Clinical Trials to Define Endpoints for Bispecific Trials in Large B-Cell Lymphoma

Dai Chihara, Micheal J. Kane, Christopher R. Flowers, Brian P. Hobbs

Blood (2024) 144 (Supplement 1): 4462.

https://doi.org/10.1182/blood-2024-193578

Published: 2024

Journal Articles

Comprehensive Characterization and Validation of the Tumor Microenvironment in Patients with Relapsed/Refractory Large B-Cell Lymphoma Identifies Subgroups with Greatest Benefit from CD19 CAR T-Cell Therapy

Blood (2024) 144 (Supplement 1): 643.

https://doi.org/10.1182/blood-2024-204166

Published: 2024

Journal Articles

Survival Outcomes and Genetic Assessment in Patients with Dual Diagnoses of B-Cell and T-Cell Lymphomas

Anath Lionel, Karmila Murphy, Amy A. Ayers, Christopher R. Flowers, Keyur P. Patel, Courtney D. DiNardo, Francisco Vega, Dai Chihara

Blood (2024) 144 (Supplement 1): 1680.

https://doi.org/10.1182/blood-2024-211432

Published: 2024

Journal Articles

Large Cell Transformation in Mycosis Fungoides & Sezary Syndrome: An Analysis of 445 Cases

Blood (2024) 144 (Supplement 1): 1679.

https://doi.org/10.1182/blood-2024-209213

Published: 2024

Journal Articles

Five-Year Analysis of the POLARIX Study: Prolonged Follow-up Confirms Positive Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) on Outcomes

Blood (2024) 144 (Supplement 1): 469.

https://doi.org/10.1182/blood-2024-197938

Published: 2024

Journal Articles

A Phase Ib, Open-Label Study of Add on Therapy with CK0804 in Participants with Myelofibrosis and Suboptimal Response to Ruxolitinib

Lucia Masarova, Meixian Huang, Swati Goel, Sharon Bledsoe, Naveen Pemmaraju, Tapan M. Kadia, Prithviraj Bose, Jo Ishizawa, Guillermo Montalban-Bravo, Mi-Ae Lyu, Tara Sadeghi, Simrit Parmar, Christopher R. Flowers, Hagop M. Kantarjian

Blood (2024) 144 (Supplement 1): 999.

https://doi.org/10.1182/blood-2024-211587

Published: 2024

Journal Articles

Retreatment with R-CHOP-like Therapy Is Active with Durable Responses in Patients with Late Relapse of Diffuse Large B-Cell Lymphoma

Eduardo Edelman Saul, Bryan Valcarcel, Amy A. Ayers, Mansoor Noorani, Dai Chihara, Fateeha Furqan, Sairah Ahmed, Swaminathan P Iyer, Sattva S. Neelapu, Luis E. Fayad, F. B. Hagemeister, Chijioke Nze, Preetesh Jain, Michael Wang, Paolo Strati, Ayushi Chauhan, Francisco Vega, Christopher R. Flowers, Jason R. Westin

Blood (2024) 144 (Supplement 1): 4454.

https://doi.org/10.1182/blood-2024-211247

Published: 2024

Journal Articles

Prospective Observational Cohort Study to Collect Granular Social Determinants of Health Data for Transplant and Cellular Therapy Candidates and Recipients

Warren B Fingrut, KaNoisha Codrington, Ligny Hunter, Ricky Garcia, Charles Martinez, Gabriela Rondon, Denái R. Milton, Christopher R. Flowers, Elizabeth J. Shpall

Blood (2024) 144 (Supplement 1): 3573.1.

https://doi.org/10.1182/blood-2024-202666

Published: 2024

Journal Articles

Outcomes in Early Relapse of Follicular Lymphoma Versus Early Histologic Transformation Following Firstline Immunochemotherapy in Follicular Lymphoma

Blood (2024) 144 (Supplement 1): 1652.

https://doi.org/10.1182/blood-2024-201078

Published: 2024

Journal Articles

An Integrated Spatial, Codex, and Genomic Analysis Predicts Responsiveness and Survival in the Phase II Combination of Pembrolizumab and Romidepsin in PTCL

Ranjit Nair, Daniela E. Duenas, Jingjing Liu, Rishab Prakash, Chen Zhou, Ayse A Koksoy, Jie Xu, Salome A McAllen, Luis Malpica, Raja Luthra, Francisco Vega, Roberto N. Miranda, Jianhua Zhang, L. Jeffrey Medeiros, Cara L Haymaker, Christopher R. Flowers, Sattva S. Neelapu, Swami P. Iyer

Blood (2024) 144 (Supplement 1): 455.

https://doi.org/10.1182/blood-2024-211900

Published: 2024

Journal Articles

Use of Molecular Immune Signatures for Frontline Treatment Selection in Patients with Advanced Stage Follicular Lymphoma

Tony Z. Zhuang, Lei Feng, Dai Chihara, Chijioke Nze, Amy A. Ayers, Mansoor Noorani, James D. Ayres, Daniela E. Duenas, Kumudha Balakrishnan, Ekaterina Nesterenko, Mark Meerson, Ksenia Zornikova, Krystle Nomie, Nikita Kotlov, Nathan Fowler, Maria Alma Rodriguez, Sattva S. Neelapu, Christopher R. Flowers, Paolo Strati

Blood (2024) 144 (Supplement 1): 2982.

https://doi.org/10.1182/blood-2024-202654

Published: 2024

Journal Articles

Subsets of Follicular Lymphoma (FL) 3B Have Divergent Biological Behavior and Clinical Outcome: Results from the Prospective Multicenter MER and LEO Cohorts

Blood (2024) 144 (Supplement 1): 1629.

https://doi.org/10.1182/blood-2024-194681

Published: 2024

Journal Articles

Neighborhood-Level Social Determinants of Health and Cardiovascular Burden in Adolescent and Young Adult Patients Treated for Hodgkin Lymphoma

Elizabeth Rodriguez, Nader Kim El-Mallawany, Sairah Ahmed, Branko Cuglievan, John Andrew Livingston, Christopher R. Flowers, Qian Xiao, Michael E. Roth, Michelle A.T. Hildebrandt

Blood (2024) 144 (Supplement 1): 6359.

https://doi.org/10.1182/blood-2024-208944

Published: 2024

Journal Articles

Evaluating the Clinical Utility of Real-Time Comprehensive Whole Exome Sequencing and RNA-Seq for Patients with Diffuse Large B-Cell Lymphoma

Blood (2024) 144 (Supplement 1): 4364.

https://doi.org/10.1182/blood-2024-209105

Published: 2024

Journal Articles

PD-1 Expression Identifies Proliferating Chronic Lymphocytic Leukemia Cells and Informs Response and Resistance to BTK Inhibitor Therapy

Andres Chang, Adam Pelletier, Donald J McGuire, Maria Tsagiopoulou, Maria Karipidou, Amy Ayers, Alyssa Leal, Michael Churnetski, Colin B O'Leary, Jeffrey M. Switchenko, Carl Davis, David A. Frank, Jean L. Koff, Jonathon B Cohen, Rafick-Pierre Sekaly, Kostas Stamatopoulos, Christopher R. Flowers, Rafi Ahmed

Blood (2024) 144 (Supplement 1): 3235.

https://doi.org/10.1182/blood-2024-200302

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Blunted CD40-responsive enhancer activation in CREBBP -mutant lymphomas can be restored by enforced CD4 T-cell engagement

End points and Outcomes in Follicular Lymphoma: What should we measure, how, and why?

Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy

Real-world impact of differences in the WHO and ICC classifications of non-Hodgkin lymphoma: a LEO cohort study analysis

Developing Novel Cellular Therapies for Cutaneous T Cell Lymphoma (CTCL): Combining Immunopeptidomics and Endogenous T Cell (ETC) Therapy Platforms to Identify and Target Shared CTCL-Associated Antigens

Utilizing Synthetic Individual Patient Level Cohorts from Machine Learning on Clinical Trials to Define Endpoints for Bispecific Trials in Large B-Cell Lymphoma

Comprehensive Characterization and Validation of the Tumor Microenvironment in Patients with Relapsed/Refractory Large B-Cell Lymphoma Identifies Subgroups with Greatest Benefit from CD19 CAR T-Cell Therapy

Survival Outcomes and Genetic Assessment in Patients with Dual Diagnoses of B-Cell and T-Cell Lymphomas

Large Cell Transformation in Mycosis Fungoides & Sezary Syndrome: An Analysis of 445 Cases

Five-Year Analysis of the POLARIX Study: Prolonged Follow-up Confirms Positive Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) on Outcomes

A Phase Ib, Open-Label Study of Add on Therapy with CK0804 in Participants with Myelofibrosis and Suboptimal Response to Ruxolitinib

Retreatment with R-CHOP-like Therapy Is Active with Durable Responses in Patients with Late Relapse of Diffuse Large B-Cell Lymphoma

Prospective Observational Cohort Study to Collect Granular Social Determinants of Health Data for Transplant and Cellular Therapy Candidates and Recipients

Outcomes in Early Relapse of Follicular Lymphoma Versus Early Histologic Transformation Following Firstline Immunochemotherapy in Follicular Lymphoma

An Integrated Spatial, Codex, and Genomic Analysis Predicts Responsiveness and Survival in the Phase II Combination of Pembrolizumab and Romidepsin in PTCL

Use of Molecular Immune Signatures for Frontline Treatment Selection in Patients with Advanced Stage Follicular Lymphoma

Subsets of Follicular Lymphoma (FL) 3B Have Divergent Biological Behavior and Clinical Outcome: Results from the Prospective Multicenter MER and LEO Cohorts

Neighborhood-Level Social Determinants of Health and Cardiovascular Burden in Adolescent and Young Adult Patients Treated for Hodgkin Lymphoma

Evaluating the Clinical Utility of Real-Time Comprehensive Whole Exome Sequencing and RNA-Seq for Patients with Diffuse Large B-Cell Lymphoma

PD-1 Expression Identifies Proliferating Chronic Lymphocytic Leukemia Cells and Informs Response and Resistance to BTK Inhibitor Therapy

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only